Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $22.7 million.

  • Crinetics Pharmaceuticals' Share-based Compensation rose 2510.06% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.1 million, marking a year-over-year increase of 4181.44%. This contributed to the annual value of $69.4 million for FY2024, which is 6949.46% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Share-based Compensation is $22.7 million, which was up 2510.06% from $26.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Share-based Compensation registered a high of $26.1 million during Q2 2025, and its lowest value of $3.4 million during Q1 2021.
  • In the last 5 years, Crinetics Pharmaceuticals' Share-based Compensation had a median value of $10.2 million in 2023 and averaged $11.9 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Share-based Compensation surged by 8614.25% in 2024 and then surged by 2510.06% in 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Share-based Compensation (Quarter) stood at $5.2 million in 2021, then skyrocketed by 54.09% to $7.9 million in 2022, then skyrocketed by 46.16% to $11.6 million in 2023, then soared by 62.22% to $18.8 million in 2024, then increased by 20.47% to $22.7 million in 2025.
  • Its last three reported values are $22.7 million in Q3 2025, $26.1 million for Q2 2025, and $20.5 million during Q1 2025.